Overall, these data imply that (a) in CML patients under different TKIs treatment, the gene expression of both large HERCs negatively correlate with the BCR-ABL transcript; (b) the mRNA amount of the large HERCs was equally and significantly downregulated at the onset stage of CML when compared to healthy counterpart; (c) the positive correlation between HERC1 and HERC2 in patients treated with Imatinib is comparatively higher (ρ = 0.667) than that observed in patients treated with Dasatinib (ρ = 0.558). Here, HERC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.